Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rim, Chai Hong | - |
dc.contributor.author | Shin, In-Soo | - |
dc.contributor.author | Yoon, Won Sup | - |
dc.contributor.author | Park, Sunmin | - |
dc.date.accessioned | 2021-08-30T18:08:38Z | - |
dc.date.available | 2021-08-30T18:08:38Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 2226-4477 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53899 | - |
dc.description.abstract | Background: Ultracentral (UC) tumors, a subset of central lung tumors defined as those that abut the proximal bronchial tree (PBT), have been contraindicated for stereotactic body radiotherapy (SBRT). The present meta-analysis evaluated the efficacy of SBRT for UC and central tumors, and dose-response for local control (LC) of UC tumors. Methods: Databases including MEDLINE and EMBASE were searched up to March, 2020, to identify studies regarding SBRT for UC and/or central tumors. The primary endpoints were LC and overall survival (OS), while secondary endpoints were grade >= 3 and 5 complications. Results: Fourteen studies including 892 patients were included. In the UC and central tumor groups, the 1-year OS rates were 82.2% and 85.4% (P=0.556), respectively, and the 2-year OS rates were 66.4% and 71.9% (P=0.522), respectively. The 1and 2-year LC rates in the UC and central tumor groups were 93.9% and 97.8% (P=0.023) and 90.4% and 93.7% (P=0.459), respectively. The pooled grade >= 3 complication rates in the UC and central tumor groups were 9.0% and 4.4% (P=0.06), while the corresponding grade 5 complication rates were 5.7% and 2.1% (P=0.087). The dose-response for LC was shown in the meta regression (P<0.0001), and 1-year LC rates were significantly different (94.4% vs. 59.3%, P<0.001) with very low heterogeneities in both subgroups, with threshold of 85 Gy10. Of the 28 fatalities, 12 (42.8%) were caused by hemorrhage or bronchial stenosis, and another 12 (42.8%) by pneumonia or respiratory failure. Conclusions: The oncologic outcomes of patients with UC and central tumors were comparable postSBRT. A dose of at least >_85 Gy10 is recommended for SBRT of UC tumors. Causes of complications should be further studied as UC tumors are more prone to serious toxicities. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AME PUBL CO | - |
dc.subject | CENTRAL LUNG-TUMORS | - |
dc.subject | ABLATIVE RADIOTHERAPY | - |
dc.subject | RADIATION-THERAPY | - |
dc.subject | OUTCOMES | - |
dc.subject | CANCER | - |
dc.subject | BIAS | - |
dc.title | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rim, Chai Hong | - |
dc.contributor.affiliatedAuthor | Yoon, Won Sup | - |
dc.identifier.doi | 10.21037/tlcr-20-503 | - |
dc.identifier.scopusid | 2-s2.0-85091703633 | - |
dc.identifier.wosid | 000573105400034 | - |
dc.identifier.bibliographicCitation | TRANSLATIONAL LUNG CANCER RESEARCH, v.9, no.4, pp.1268 - + | - |
dc.relation.isPartOf | TRANSLATIONAL LUNG CANCER RESEARCH | - |
dc.citation.title | TRANSLATIONAL LUNG CANCER RESEARCH | - |
dc.citation.volume | 9 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1268 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | CENTRAL LUNG-TUMORS | - |
dc.subject.keywordPlus | ABLATIVE RADIOTHERAPY | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | BIAS | - |
dc.subject.keywordAuthor | Lung cancer | - |
dc.subject.keywordAuthor | central tumor | - |
dc.subject.keywordAuthor | ultracentral (UC) tumor | - |
dc.subject.keywordAuthor | stereotactic body radiotherapy (SBRT) | - |
dc.subject.keywordAuthor | stereotactic ablative body radiotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.